(Q34086032)

30 July 2017

1 reference

title

Clinical potential of emerging new agents in hepatitis B. (English)

1 reference

30 July 2017

Farrell GC

1

1 reference

30 July 2017

1 October 2000

1 reference

30 July 2017

1 reference

30 July 2017

60

1 reference

30 July 2017

4

1 reference

30 July 2017

701-710

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060040-00001

30 July 2017

0 references

cites work

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

12 December 2020

Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis

1 reference

12 December 2020

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin

1 reference

12 December 2020

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

12 December 2020

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine

1 reference

12 December 2020

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

12 December 2020

A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.

1 reference

12 December 2020

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

12 December 2020

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

12 December 2020

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

12 December 2020

Liver transplantation in chronic hepatitis B and C.

1 reference

12 December 2020

Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B

1 reference

12 December 2020

Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation?

1 reference

12 December 2020

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection

1 reference

12 December 2020

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

12 December 2020

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

1 reference

12 December 2020

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

12 December 2020

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes

1 reference

12 December 2020

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure

1 reference

12 December 2020

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

12 December 2020

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

12 December 2020

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

12 December 2020

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

1 reference

12 December 2020

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

12 December 2020

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

12 December 2020

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

12 December 2020

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

12 December 2020

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

12 December 2020

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

12 December 2020

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

12 December 2020

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

12 December 2020

Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

1 reference

12 December 2020

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Perspectives for the treatment of hepatitis B virus infections

1 reference

12 December 2020

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

1 reference

12 December 2020

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

12 December 2020

Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy

1 reference

12 December 2020

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

12 December 2020

10.2165/00003495-200060040-00001

Identifiers

DOI

1 reference

PubMed ID

11085196

Dimensions Publication ID

30 July 2017

1002080311

0 references

Fatcat ID

release_hdmzrjttjrdydgz367mz4kbifm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hdmzrjttjrdydgz367mz4kbifm

24 November 2022

mapped directly with Wikidata item

PubMed ID

11085196

1 reference

PubMed ID

11085196